Cargando…

Fosfomycin, Applying Known Methods and Remedies to A New Era

The exponential increase in the numbers of isolates of Carbapenem-Resistant Enterobacteriaceae (CRE) creates the need for using novel therapeutic approaches to save the lives of patients. Fosfomycin has long been considered a rational option for the treatment of CRE to be used as part of a combined...

Descripción completa

Detalles Bibliográficos
Autores principales: M., Viviana Albán, Mariño-Brito, Estefanía, Villavicencio, Fernando, Satán, Carolina, Villacís, José E., Gestal, Mónica C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564589/
https://www.ncbi.nlm.nih.gov/pubmed/32784746
http://dx.doi.org/10.3390/diseases8030031
_version_ 1783595749291851776
author M., Viviana Albán
Mariño-Brito, Estefanía
Villavicencio, Fernando
Satán, Carolina
Villacís, José E.
Gestal, Mónica C.
author_facet M., Viviana Albán
Mariño-Brito, Estefanía
Villavicencio, Fernando
Satán, Carolina
Villacís, José E.
Gestal, Mónica C.
author_sort M., Viviana Albán
collection PubMed
description The exponential increase in the numbers of isolates of Carbapenem-Resistant Enterobacteriaceae (CRE) creates the need for using novel therapeutic approaches to save the lives of patients. Fosfomycin has long been considered a rational option for the treatment of CRE to be used as part of a combined therapy scheme. However, the assessment of fosfomycin susceptibility in the laboratory presents a great challenge due to the discrepancies found between different methodologies. Thus, our goal was to evaluate fosfomycin susceptibility in a group of 150 Enterobacteriaceae bacterial isolates using agar dilution as the gold standard technique to compare the results with those obtained by disk diffusion. We found a fosfomycin susceptibility of 79.3% in general terms. By comparing both methodologies, we reported a categorical agreement of 96% without Very Major Errors (VMEs) or Major Errors (MEs) and 4% of minor Errors (mEs). Our results suggest that fosfomycin could provide a rational alternative treatment for those patients that are infected by a Multidrug-Resistant (MDR) microorganism that is currently untreatable and that the disk diffusion and classical agar dilution techniques are adequate to assess the resistance profile of CRE to fosfomycin.
format Online
Article
Text
id pubmed-7564589
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75645892020-10-29 Fosfomycin, Applying Known Methods and Remedies to A New Era M., Viviana Albán Mariño-Brito, Estefanía Villavicencio, Fernando Satán, Carolina Villacís, José E. Gestal, Mónica C. Diseases Article The exponential increase in the numbers of isolates of Carbapenem-Resistant Enterobacteriaceae (CRE) creates the need for using novel therapeutic approaches to save the lives of patients. Fosfomycin has long been considered a rational option for the treatment of CRE to be used as part of a combined therapy scheme. However, the assessment of fosfomycin susceptibility in the laboratory presents a great challenge due to the discrepancies found between different methodologies. Thus, our goal was to evaluate fosfomycin susceptibility in a group of 150 Enterobacteriaceae bacterial isolates using agar dilution as the gold standard technique to compare the results with those obtained by disk diffusion. We found a fosfomycin susceptibility of 79.3% in general terms. By comparing both methodologies, we reported a categorical agreement of 96% without Very Major Errors (VMEs) or Major Errors (MEs) and 4% of minor Errors (mEs). Our results suggest that fosfomycin could provide a rational alternative treatment for those patients that are infected by a Multidrug-Resistant (MDR) microorganism that is currently untreatable and that the disk diffusion and classical agar dilution techniques are adequate to assess the resistance profile of CRE to fosfomycin. MDPI 2020-08-07 /pmc/articles/PMC7564589/ /pubmed/32784746 http://dx.doi.org/10.3390/diseases8030031 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
M., Viviana Albán
Mariño-Brito, Estefanía
Villavicencio, Fernando
Satán, Carolina
Villacís, José E.
Gestal, Mónica C.
Fosfomycin, Applying Known Methods and Remedies to A New Era
title Fosfomycin, Applying Known Methods and Remedies to A New Era
title_full Fosfomycin, Applying Known Methods and Remedies to A New Era
title_fullStr Fosfomycin, Applying Known Methods and Remedies to A New Era
title_full_unstemmed Fosfomycin, Applying Known Methods and Remedies to A New Era
title_short Fosfomycin, Applying Known Methods and Remedies to A New Era
title_sort fosfomycin, applying known methods and remedies to a new era
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564589/
https://www.ncbi.nlm.nih.gov/pubmed/32784746
http://dx.doi.org/10.3390/diseases8030031
work_keys_str_mv AT mvivianaalban fosfomycinapplyingknownmethodsandremediestoanewera
AT marinobritoestefania fosfomycinapplyingknownmethodsandremediestoanewera
AT villavicenciofernando fosfomycinapplyingknownmethodsandremediestoanewera
AT satancarolina fosfomycinapplyingknownmethodsandremediestoanewera
AT villacisjosee fosfomycinapplyingknownmethodsandremediestoanewera
AT gestalmonicac fosfomycinapplyingknownmethodsandremediestoanewera